Abstract. Breast cancer is one of the most common malignancies and the leading cause of cancer-associated death among women. Anterior gradient 3 (AGR3) is a cancer-associated gene and is similar to its homologous oncogene AGR2. However, whether AGR3 participates in breast cancer progression remains unclear. The present study aimed to investigate the function of AGR3 in ER-positive breast cancer. In the present study, reverse transcription-quantitative PCR was used to detect AGR3 mRNA expression in breast cancer tissues and cell lines; linear correlation analysis was used to investigate the correlation between AGR3 and estrogen receptor 1 (ESR1) expression in breast cancer via GEO dataset analysis; western blotting was used to assess the levels of AGR3, ER and GAPDH; small interfering (si)RNA transfection was used to knock down AGR3 and ESR1 expression; and finally the Cell Counting Kit-8 assay was used to evaluate cell viability. In the present study, AGR3 expression was markedly increased in estrogen receptor (ER)-positive breast cancer tissues and cell lines compared with that in ER-negative breast cancer. AGR3 expression was upregulated in estrogen-treated T47D cells, whereas 4-hydroxytamoxifen, an inhibitor of estrogen-ER activity in breast cancer cells, downregulated AGR3 expression in T47D cells. Functional assays demonstrated that knockdown of AGR3 using siRNAs inhibited T47D cell proliferation compared with that of the negative control group. Additionally, AGR3 expression was decreased after knocking down ESR1. The present results suggested that AGR3 may serve an important role in estrogen-mediated cell proliferation in breast cancer and that AGR3 knockdown may be a potential therapeutic strategy for ER-positive breast cancer.

Introduction

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-associated death among women worldwide (1). In 2018, the International Agency for Research on Cancer estimated a disease incidence rate of 24.2% and mortality rate of 15.0% in women across 185 countries (1). Breast cancer is divided into four subtypes according to the 2015 St. Gallen consensus (2): Luminal A-like, luminal B-like, human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes, which are based on estrogen receptor (ER), progesterone receptor (PR), Ki-67 and HER2 immunohistochemical status (2). ERα is a nuclear transcription factor encoded by the estrogen receptor 1 (ESR1) gene and activated by estrogen (3). ERα has different effects in normal breast epithelial cells and breast cancer cells, and it serves a predictive role in the response to endocrine therapies (4). Estrogen promotes cell proliferation and breast cancer development in an ER-dependent manner (5); in turn, ERα promotes breast cancer tumorigenesis and progression (6,7). Therefore, estrogens serve an essential role in regulating breast cancer cell proliferation, and estrogen-activated ERα is a crucial factor for breast cancer development and therapy.

Anterior gradient protein 3 (AGR3) is a member of the protein disulfide isomerase (PDI) gene family, which consists of 21 members (http://www.genenames.org/cgi-bin/genefamilies/set/692), and AGR3 also has two AGR subfamilies, AGR1 and AGR2 (8,9). AGR2 has been widely investigated in breast cancer; however, AGR3 remains largely unexplored.
cancer and is known to participate in numerous aspects of its development and therapy, including cell proliferation and migration (10,11). Although AGR3 and AGR2 are highly similar homologous genes, the function of AGR3 in cancer may not be the same as that of the metastasis-associated AGR2 (12). AGR3 is upregulated in serous borderline ovarian tumor compared with serous ovarian carcinoma, and high levels of AGR3 predict a longer survival time in patients with serous ovarian carcinoma (13). In prostate cancer cells, AGR3 is upregulated by androgens and estrogen in an androgen receptor dependent manner (14). Additionally, AGR3 is highly expressed in intrahepatic cholangiocarcinoma compared with its expression levels in hepatocellular carcinoma (15). In breast cancer, AGR3 is positively associated with low histological grade breast tumors (16). Recent studies have demonstrated that extracellular AGR3 can regulate breast cancer cell migration via Src signaling (17), and that AGR3 can promote the proliferative and invasive abilities of breast cancer cells, as well as chemotherapy response (18).

Although differential expression of AGR3 has been identified among different types of cancer, including ovarian, prostate, liver and breast cancers (13-16), the role of AGR3 in breast cancer oncogenesis and development remains unclear. The present study aimed to investigate the association between AGR3 and ER status, and the function of AGR3 in ER-positive breast cancer. It was hypothesized that AGR3 may promote breast cancer development in an ER-dependent manner, and AGR3 may serve as a potential therapeutic target for patients with ER-positive breast cancer.

Materials and methods

Tissue sample collection. A total of 72 breast tumor and paired adjacent normal tissue samples were collected from 72 patients with breast cancer (age range, 30-74 years; median age, 46 years) at The First Affiliated Hospital of Chongqing Medical University (Chongqing, China) between July 2017 and October 2017. Female patients with primary breast cancer, normal cardiopulmonary function and willingness to undergo breast surgery were included, while patients with secondary breast cancer, intolerable or unwilling to undergo breast surgery, and male patients with breast cancer were excluded from the present study. All patients signed informed consent for the retention and analysis of their tissues for research purposes. Breast tumor and paired normal tissue samples (>3 cm from the primary tumor boundary) were collected after surgery and immediately transferred to liquid nitrogen for fast-frozen storage and long-term storage at -80°C. The collection of tumor samples and patient information was approved by the Ethics Committee of The First Affiliated Hospital of Chongqing Medical University (approval no. 2017-16).

Cell culture and drug treatment. MCF7, T47D, ZR75-1, BT549, MDA-MB-231, MDA-MB-468 and SK-BR-3 cell lines were obtained from the American Type Culture Collection. T47D and ZR75-1 cells were cultured at 37°C with 5% CO2 in RPMI-1640 medium, whereas the other cell lines were grown in DMEM, both RPMI-1640 and DMEM medium were supplemented with 10% FBS (all Gibco; Thermo Fisher Scientific, Inc.). Before adding estrogen (MedChemExpress, Inc.), cells in the logarithmic growth phase were seeded in 6-well plates at a confluence of 60-70% and were serum-starved for 24 h in DMEM. RNA was extracted from estrogen-treated cells at different time points (0, 1, 3, 6, 12 and 24 h). For 4-hydroxy-tamoxifen (4-OH Tam; MedChemExpress, Inc.) treatment, cells in the logarithmic growth phase were seeded in 6-well plates at a confluence of 60-70% and cultured in DMEM supplemented with 10% FBS. Different concentrations of 4-OH Tam (0, 2, 4, 6, 8 and 10 µmol) were added, and RNA and proteins were extracted after 24 h for RT-qPCR and western blot analysis.

siRNA transfection. The siRNAs sequences used to target AGR3 and ESR1 (Shanghai GenePharma Co., Ltd.) were as follows: AGR3-siRNA1 forward, 5'-CAGAUUGUACAC AUAAUAG-3' and reverse, 5'-CUCAUUGUACAAUCA G-3'; AGR3-siRNA2 forward, 5'-AGUUUCAAUGCUAAC ACCU-3' and reverse, 5'-AGGUUUAAGCAUAAGAAU-3'; ESR1-siRNA1 forward, 5'-GGAGGAUGUGAAACACAA TTT-3' and reverse, 5'-UUGUUGUUCAACAUUCCTT-3'; and ESR1-siRNA2 forward, 5'-GGAUUUCAACCCUCAUGA UTT-3' and reverse, 5'-AUAAUGAGGUGCAAAUUCCTT-3'. T47D cells (at a confluence of 60-70%) were transfected with siRNAs (100 nM) using Lipofectamine® RNAiMAX reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The culture medium was changed after 4-6 h, and knockdown efficiencies were determined by RT-qPCR after 24 h.

RNA extraction and qPCR analysis. Total RNA was extracted from breast cancer tissues and cells using TRIzol reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol, and the RNA concentration was measured using a NanoDrop ND-2000 (Thermo Fisher Scientific, Inc.). cDNA was synthesized from 1 µg total RNA with a PrimeScript II cDNA Synthesis kit (37°C for 15 min, 85°C for 5 sec, 4°C for short preservation (usually 30 min prior to qPCR); Takara Bio, Inc.). Targeted genes were detected with a SYBR Premix Ex Taq II qPCR kit (Takara Bio, Inc.) using a primer mixture, and cDNA was amplified by CFX96 fluorescence qPCR (thermocycling conditions: Initial denaturation at 95°C for 2 min; 40 cycles of denaturation at 95°C for 30 sec, annealing at 58°C for 30 sec, elongation at 72°C for 20 sec; and a final extension at 65°C for 5 sec; Bio-Rad Laboratories, Inc.). Gene-specific primer sequences were designed as follows: AGR3 forward, 5'-AGAGGGCTCTCCTAGACACTC-3' and reverse, 5'-GGC ACATAATTGCCCATACGGT-3'; ESR1 forward, 5'-GGTCAG TGCCCTGGTGGATG-3' and reverse, 5'-CAGGTGTTGAG TAAGC-3'; GAPDH forward, 5'-TTCCAGGACCGAG CATCC-3' and reverse, 5'-GGCTTGTGTCATACCTTCTC A-3'; Growth regulation by estrogen in breast cancer 1 (GREB1) forward, 5'-AAATCCGAAGATGTTGAGT-3' and reverse, 5'-TCTCACCAAGCAGGAGGA-3'. mRNA abundance was calculated according to the 2^(-ΔΔCT) method (19), relative to the internal control GAPDH.

Protein extraction and western blot analysis. Total protein from cell lines was extracted on ice using RIPA lysis buffer (Thermo Fisher Scientific, Inc.). Protein concentration was quantified using a Pierce™ BCA Protein assay kit.
seeded into 96-well plates at a density of 5x10^3 cells/well. Cells were harvested and cell viability was assessed using the Cell Counting Kit-8 (CCK-8) cell viability test. GAPDH expression was determined by ImageJ software (version 1.8.0; National Institutes of Health). AGR3 expression was quantified according to the gray value and normalized to the highest GAPDH expression. The top 10% of the data with the highest AGR3 expression were defined as the low expression group, and the bottom 10% (110) of the date with the lowest AGR3 expression were defined as the low expression group. The R script of GSEA from the Broad Institute (https://www.gsea-msigdb.org/gsea) was used for the GSEA analysis of the two groups.

**Statistical analysis.** All the statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, Inc.) and R 3.4.0 (https://www.r-project.org), for GSEA analysis. The statistical significance of GSEA analysis was determined by unpaired Student's t-test. The statistical significance of paired groups was determined by Wilcoxon matched-pairs signed-rank test. The statistical significance of unpaired two groups was determined by Mann-Whitney test. Pearson's correlation analysis was performed to analyze the correlation of target genes. Multiple groups were statistically compared using one-way ANOVA and Dunnett's multiple comparisons test. The results are presented as the mean ± standard deviation (n≥3). P<0.05 was considered to indicate a statistically significant difference.

**Results**

AGR3 expression is upregulated in luminal breast cancer tissues and is positively correlated with ESR1 expression. To investigate AGR3 expression in breast cancer, AGR3 expression was analyzed in ER-positive and ER-negative paired cancer tissues and adjacent normal tissues by RT-qPCR. AGR3 expression was significantly upregulated in luminal A breast cancer tissues compared with that in their paired adjacent normal tissues (n=21; Tumor, 0.3335±0.0719 vs. normal, 0.2704±0.1231; P=0.0421; Fig. 1A), and was visibly increased in luminal B breast cancer tissues compared with normal tissues (n=23; Tumor, 0.3344±0.2599 vs. normal, 0.0279±0.0084; P=0.0605; Fig. 1B). Among the 44 pairs of ER-positive breast cancer and adjacent normal tissues, the RNA levels of AGR3 were significantly upregulated in breast cancer tissues compared with that in paired normal tissues (n=44; Tumor, 0.3340±0.1386 vs. normal, 0.1436±0.0610; P=0.0016; Fig. 1C). Additionally, AGR3 RNA expression was detected in patients with TN breast cancer and was significantly downregulated in ER-negative TN breast cancer tissues compared with that in normal adjacent tissues (n=28; Tumor, 0.0017±0.0006 vs. normal, 0.1197±0.0514; P=0.0001; Fig. 1D).

AGR3 expression between ER-positive and ER-negative breast cancer tissues, as well as between their paired ER-positive and ER-negative adjacent normal tissues was analyzed. AGR3 RNA levels were significantly upregulated in ER-positive (n=44) compared with in ER-negative (n=28) breast cancer tissues (BC ER+, 0.3340±0.1386 vs. BC ER-, 0.0017±0.0006; P<0.0001; Fig. 1E), although this difference was not observed between ER-positive (n=44) and ER-negative (n=28) adjacent normal tissues (paracancer ER+, 0.1436±0.0610 vs. paracancer ER-, 0.1197±0.0514; P=0.5994; Fig. 1F), suggesting that AGR3 may be a tumor-specific gene that is upregulated in breast cancer depending on the ER status. To confirm the present findings, the correlation between AGR3 and ESR1 expression was analyzed using the GEO datasets. The correlation coefficients in three GEO datasets were analyzed, and all displayed significant positive correlations between AGR3 and ESR1 expression (GSE5460, r=0.6633; 95% CI: 0.554-0.7502; GSE19615, r=0.653; 95% CI: 0.565-0.7328; GSE37709, r=0.7298; 95% CI: 0.620-0.8079).
AGR3 is associated with the estrogen response and cancer-associated signaling pathways according to GSEA. To comprehensively understand the role of AGR3 in breast cancer, GSEA was performed to explore the potential pathways associated with AGR3. GSEA is an analytical method that can reveal the biological pathways of candidate genes from gene sets (26). A total of 186 KEGG gene sets from the MSigDB were used for the GSEA, and a number of AGR3-associated gene sets were identified (Fig. 2A and Table I). AGR3 was positively associated with the ‘HALLMARK_ESTROGEN_RESPONSE_EARLY’ [enrichment score (ES)=0.6592; normalized ES (NES)=2.5579; nominal P-value (Nom P<0.0001; false discovery rate q-value (FDR q-val)=0; family-wise error rate P-value (FWER P<0.0001; Fig. 2B) and the ‘HALLMARK_ESTROGEN_RESPONSE_LATE’ (ES=0.57267; NES=2.2178; NOM P<0.0001; FDR q-val=0; FWER P<0.0001; Fig. 2C) gene sets, indicating that AGR3 may function as an estrogen response factor. Additionally, AGR3 was negatively associated with ‘HALLMARK_E2F_TARGETS’ (ES=-0.64839; NES=-2.4647; NOM P<0.0001; FDR q-val=0; FWER P<0.0001; Fig. 2D), allograft rejection, G2/M checkpoint, mitotic spindle, interferon γ response, Myc targets, mTORc1 signaling and other gene sets (Fig. 2A and Table I), indicating that AGR3 may function in different cancer-associated signaling pathways in breast cancer.

AGR3 is regulated by estrogen in T47D cells. To explore the possible association between AGR3 and ESR1, the RNA expression levels of AGR3 in different breast cancer cell lines, including the ER-positive breast cancer MCF7, ZR75-1 and T47D cell lines and the ER-negative breast cancer MB231, MB468, BT549 and SKBR-3 cell lines, were detected. AGR3 RNA expression was markedly upregulated in T47D cells and was relatively abundant in the ZR75-1 cell line, whereas very low levels were observed in the other ER-negative breast cancer cell lines (MCF7, 0.0009±0.0001; T47D, 6.8700±0.3437; ZR75-1, 1.0000±0.0000 (for the convenience of comparing with other cell lines, ZR75-1 was normalized to 1); BT549, NA (not available value that was too low to detect); MB231, NA; MB468, 0.0013±0.0001; and SKBR-3, 5.443x10^-5±5.862x10^-6;
Fig. 3A). To confirm AGR3 protein expression in breast cancer cell lines, AGR3 protein levels were detected using an AGR3 antibody. AGR3 protein was highly expressed in T47D and ZR75-1 cells compared with the other cell lines (MCF7, BT549, MB231, MB468 and SKBR-3). However, the AGR3 protein was lowly expressed in ER-negative breast cancer cell lines, including BT549, MB231, MB468 and SKBR-3 cells (Fig. 3B), consistent with the findings at the RNA level. ER
Table I. Gene Set Enrichment Analysis results of hallmark gene sets of anterior gradient 3 in breast cancer.

| Gene set                                                | Size | ES        | NES       | NOM P-value | FDR q-value | FWER P-value | Gene ratio |
|---------------------------------------------------------|------|-----------|-----------|-------------|-------------|--------------|------------|
| HALLMARK_ESTROGEN_RESPONSE_EARLY                        | 196  | 0.65919   | 2.5579    | <0.0001     | 0.00000000  | <0.0001      | 0.0845     |
| HALLMARK_ESTROGEN_RESPONSE_LATE                         | 197  | 0.57267   | 2.2178    | <0.0001     | 0.00000000  | <0.0001      | 0.0970     |
| HALLMARK_PEROXISOME                                      | 103  | 0.41390   | 1.4776    | 0.0113100   | 0.05423300  | 0.1878       | 0.1120     |
| HALLMARK_E2F_TARGETS                                    | 196  | -0.64839  | -2.4647   | <0.0001     | 0.00000000  | <0.0001      | 0.1520     |
| HALLMARK_ALLOGRAFT_REJECTION                            | 199  | -0.63245  | -2.4169   | <0.0001     | 0.00000000  | <0.0001      | 0.2010     |
| HALLMARK_G2M_CHECKPOINT                                 | 194  | -0.63038  | -2.3917   | <0.0001     | 0.00000000  | <0.0001      | 0.1380     |
| HALLMARK/MITOTIC_SPINDLE                                | 198  | -0.51817  | -1.9722   | <0.0001     | 0.00000000  | <0.0001      | 0.2300     |
| HALLMARK_INTERFERON_GAMMA_RESPONSE                      | 198  | -0.50047  | -1.9088   | <0.0001     | 0.00009480  | 0.0004       | 0.2280     |
| HALLMARK_MYC_TARGETS_V1                                 | 197  | -0.49912  | -1.9013   | <0.0001     | 0.00013949  | 0.0007       | 0.3410     |
| HALLMARK_INFLAMMATORY_RESPONSE                          | 196  | -0.49297  | -1.8694   | <0.0001     | 0.00020188  | 0.0012       | 0.2130     |
| HALLMARK_IL6_JAK_STAT3_SIGNALING                        | 87   | -0.54467  | -1.8545   | <0.0001     | 0.00023175  | 0.0016       | 0.1880     |
| HALLMARK_TNFA_SIGNALING_VIA_NFKB                        | 198  | -0.47236  | -1.7999   | <0.0001     | 0.00039442  | 0.0031       | 0.2300     |
| HALLMARK_MYC_TARGETS_V2                                 | 58   | -0.56107  | -1.7859   | 0.0003642   | 0.00040505  | 0.0035       | 0.2310     |
| HALLMARK_MTORC1_SIGNALING                               | 197  | -0.43572  | -1.6602   | <0.0001     | 0.00028831  | 0.0266       | 0.2200     |
| HALLMARK_KRAS_SIGNALING_UP                              | 195  | -0.40799  | -1.5502   | 0.0003493   | 0.01011000  | 0.0989       | 0.1380     |

ES, enrichment score; NES, normalized ES; NOM, nominal; FDR, false discovery rate; FWER, family-wise error rate.
protein was also expressed in all the ER-positive breast cancer cell lines; however, no ER protein was detected in ER-negative BT549, MB231, MB468 and SKBR-3 cell lines (Fig. 3B).

Estrogen is an important factor in breast cancer, and it can directly activate the ER (27). To examine whether estrogen regulates AGR3 expression, estrogen was added to T47D and ZR75-1 cells at a final concentration of 10 nmol, and the RNA level of AGR3 at different time intervals after treatment was detected. Although the RNA levels of GREB1, an estrogen response molecule (28), were gradually increased and reached the highest level after 12 h of estrogen treatment in ZR75-1 cells (12 h, 9.1120±0.2447 vs. 0 h, 1.0000±0.0000 (0 h was normalized to 1); P<0.0001; one-way ANOVA, F=512.4 and P<0.0001), AGR3 did not appear to be significantly increased in ZR75-1 cells treated with estrogen for 12 h (12 h, 1.3008±0.1390 vs. 0 h, 1.0000±0.0000; P=0.0368) or 24 h (24 h, 1.3900±0.08388 vs. 0 h, 1.0000±0.0000; P=0.0085; one-way ANOVA, F=14.8 and P<0.0001; Fig. 3C). However, the RNA expression levels of AGR3 and GREB1 were increased in a similar manner in T47D cells, and both reached their highest levels after estrogen treatment for 12 h (AGR3: 12 h, 2.043±0.05334 vs. 0 h, 1.0000±0.0000 (0 h was normalized to 1); P<0.0001; one-way ANOVA, F=110.6 and P<0.0001; GREB1: 12 h, 2.274±0.08661 vs. 0 h, 1.0000±0.0000 (0 h was normalized to 1); P<0.0001; one-way ANOVA, F=77.2 and P<0.0001; Fig. 3D), suggesting that AGR3 may be regulated by estrogen in ER-positive breast cancer cells.

To further investigate the association between estrogen and AGR3, the present study assessed whether 4-OH Tam may influence the viability of T47D cells and the expression levels of AGR3. When different concentrations of 4-OH Tam were added to T47D cells, cell viability was significantly decreased with increasing 4-OH Tam concentrations, and was the lowest after the addition of 10 µmol 4-OH Tam (10 µmol, 1.5030±0.0052 vs. 0 µmol, 2.2510±0.0092; P<0.0001; one-way ANOVA, F=48.2 and P<0.0001; Fig. 4A). Additionally, the protein levels of AGR3 and ER were analyzed; these appeared to decrease following 4-OH Tam treatment, with protein levels of AGR3 in T47D cells reaching their lowest level using 6 µmol 4-OH Tam, and ER protein levels also had a visible decline following addition of 6 µmol 4-OH Tam (Fig. 4B). Additionally, AGR3 and ESR1 RNA expression was significantly decreased in T47D cells following treatment with different concentrations of 4-OH Tam. ESR1 and AGR3 RNA expression reached their lowest levels in T47D cells using 6 µmol 4-OH Tam (ESR1: 6 µmol, 0.5301±0.0282 vs. 0 µmol, 1.0000±0.0000 (0 µmol was normalized to 1); P=0.0015; one-way ANOVA, F=16.9 and P<0.0001; AGR3: 6 µmol, 0.3810±0.0212 vs. 0 µmol, 1.0000±0.0000 (0 µmol was normalized to 1); P<0.0001; one-way ANOVA, F=65.8 and P<0.0001; Fig. 4C and D).

Therefore, both ESR1 and AGR3 expression may be regulated by 4-OH Tam, which further confirmed the effect of estrogen on AGR3 RNA and protein expression.

**AGR3 promotes T47D cell proliferation in an estrogen-dependent manner.** To further explore the role of AGR3...
in ER-positive breast cancer, the present study analyzed whether AGR3 expression may influence the ER status by knocking down AGR3 expression in T47D cells using two siRNAs. Both siRNAs significantly decreased AGR3 RNA levels (siAGR3-1, 0.5265±0.0150 vs. si-NC, 1.0000±0.0000; P<0.0001; siAGR3-2, 0.4257±0.0243 vs. si-NC, 1.0000±0.0000; P<0.0001; one-way ANOVA, F=345.2 and P<0.0001; Fig. 5A). The protein levels of AGR3 decreased after transfecting T47D cells with the AGR3 siRNAs, but there was no notable change in ER protein expression (Fig. 5B). After knocking down AGR3 using siRNAs, the viability of T47D cells was significantly decreased compared with that of the negative control cells 24 h post-transfection (siAGR3-1, 0.4383±0.007 vs. si-NC 0.5259±0.0029; P<0.0001; siAGR3-2, 0.3883±0.00625 vs. si-NC, 0.5259±0.002963; P<0.0001; one-way ANOVA, F=150.5 and P<0.0001; Fig. 5A). The protein levels of AGR3 decreased after transfecting T47D cells with the AGR3 siRNAs, but there was no notable change in ER protein expression (Fig. 5B). After knocking down AGR3 using siRNAs, the viability of T47D cells was significantly decreased compared with that of the negative control cells 24 h post-transfection (siAGR3-1, 0.4383±0.007 vs. si-NC 0.5259±0.002963; P<0.0001; siAGR3-2, 0.3883±0.00625 vs. si-NC, 0.5259±0.002963; P<0.0001; one-way ANOVA, F=150.5 and P<0.0001; Fig. 5A). The protein levels of AGR3 decreased after transfecting T47D cells with the AGR3 siRNAs, but there was no notable change in ER protein expression (Fig. 5B).

Discussion

AGR2 and AGR3 both belong to the PDI family, and they are similarly expressed in breast cancer due to the 71% similarity in their protein sequences and adjacent positions at 7p21 (29). AGR2 is a widely accepted oncogene in breast cancer and is regulated by estrogen in normal breast tissue and ER-positive breast cancer cells (30,31). Although AGR2 and AGR3 share sequence homology, they are not identical in function, and AGR3 may serve a different role in breast cancer (12). Recent studies have revealed the oncogenic functions of AGR3 in breast cancer. For example, extracellular AGR3 was demonstrated to regulate breast cancer cell migration via Src signaling, which provided an exogenous mode of expression (17), whereas the present study focused on endogenous AGR3 and its function in ER-positive breast cancer cells. In addition, AGR3 promotes the proliferative and invasive abilities of breast cancer cells and chemotherapy response (18), which further confirmed the oncogenic role of AGR3 in breast cancer. In order to fully understand the function of AGR3 in breast cancer, the present study aimed to explore the function of AGR3 in ER-positive breast cancer, and focused on the direct association between AGR3 and ER.
In the present study, AGR3 expression was significantly upregulated in ER-positive compared with ER-negative breast cancer tissues. Considering the close association between AGR3 and ER status, and that ER is a key molecule in distinguishing between low- and high-grade breast cancer, AGR3 RNA expression was detected in ER-positive and ER-negative breast cancer tissues and their paired adjacent normal breast tissues. AGR3 expression was significantly upregulated in luminal breast cancer tissues compared with that in paired adjacent normal tissues, and was significantly downregulated in TN breast cancer tissues compared with that in paired adjacent normal tissues. The results of the present study suggest that there may be different modes of AGR3 expression between ER-positive and ER-negative breast cancer. However, further studies are required to determine whether differential expression tendencies of AGR3 have the same or different function in ER-positive and ER-negative breast cancers. Of note, no differences were observed in AGR3 expression between ER-positive and ER-negative adjacent normal tissues, indicating that the differential expression tendency only occurred in breast cancer samples. Therefore, AGR3 may be a tumor-specific gene, and its expression may depend on the ER status of the breast.

In conclusion, the results of the present study demonstrated that AGR3 was an estrogen response molecule in ER-positive breast cancer. Furthermore, AGR3 was also negatively associated with several cancer-associated gene sets, such as ‘E2F_TARGETS’, ‘G2M_CHECKPOINT’ and ‘MITOTIC_SPINDLE’, which are associated with the cell cycle regulation; as well as ‘ALLOGRAFT_REJECTION’, ‘IL6_JAK_STAT3_SIGNALING’, ‘TNFA_SIGNALING_VIA_NFKB’, which are associated with immunity and inflammation; ‘EPITHELIAL_MESENCHYMAL_TRANSITION’ and ‘WNT_BETA_CATENIN_SIGNALING’, which are associated with epithelial-mesenchymal transition. Therefore, the function of AGR3 in breast cancer requires further investigation.

Figure 5. AGR3 promotes T47D cell proliferation in an estrogen-dependent manner. (A) RNA levels of AGR3 were detected by RT-qPCR after knocking down AGR3 in T47D cells. (B) Protein levels of AGR3 and ER were detected by western blotting after knocking down AGR3 in T47D cells. (C) Cell viability was detected using the Cell Counting Kit-8 assay after knocking down AGR3 in T47D cells for 2 consecutive days. (D) RNA levels of AGR3 and ESR1 were detected by RT-qPCR after knocking down ESR1 in T47D cells. Each experiment was repeated ≥3 times. “P<0.01; "P<0.001; ""P<0.0001 vs. si-NC. RT-qPCR, reverse transcription-quantitative PCR; siRNA, small interfering RNA; si-NC, small interfering negative control; AGR3, anterior gradient 3; ER, estrogen receptor; ESR1, estrogen receptor 1.
Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81772979).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LJ, JX, HY, KT, CY and KL performed the experiments and analyzed the data. SL provided the reagents, designed the experiments and critically revised the manuscript. LJ, SG and RC designed the study and drafted the initial manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The collection of tumor samples and patient information was approved by the Ethics Committee of The First Affiliated Hospital of Chongqing Medical University. The present study was supported by the National Natural Science Foundation of China (grant no. 81772979). The dataset used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Patient consent for publication

The authors declare that they have no competing interests.

Competing interests

The authors declare that they have no competing interests.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
2. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thirlwall B, Senn HJ and Palace M: Tailoring therapies—improving the management of early breast cancer: A gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26: 1533-1546, 2015.
3. Allred DC: Issues and updates: Evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol 23 (Suppl 2): S52-S59, 2010.
4. Bai Z and Gust R: Breast cancer, estrogen receptor and ligands. Arch Pharm (Weinheim) 342: 133-149, 2009.
5. Yue W, Yager JD, Wang JP, Jupe ER and Santen RJ: Estrogen receptor and ligands. Breast Cancer Res Treat 108: 191-201, 2008.
6. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Auer MR, Russnes HG, Ramnberg JA, Johnsen H, Navon R, Rodland E, et al: miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 6: e16915, 2011.
7. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szzlasi Z, Iglehart JD, et al: Amplification of APTMP4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16: 214-218, 2010.
8. Love MJ, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15: 550, 2014.
9. Durbin BP, Hardin JS, Hawkins DM and Rocke DM: A variance-stabilizing transformation for gene-expression microarray data. Bioinformatics 18 (Suppl 1): S105-S110, 2002.
10. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550, 2005.
11. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282, 2006.
28. Mohammed H, D’Santos C, Serandour AA, Ali HR, Brown GD, Atkins A, Rueda OM, Holmes KA, Theodorou V, Robinson JL, et al: Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep 3: 342-349, 2013.

29. Fletcher GC, Patel S, Tyson K, Adam PJ, Schenker M, Loader JA, Daviet L, Legrain P, Parekh R, Harris AL and Terrett JA: hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer 88: 579-585, 2003.

30. Hrstka R, Nenutil R, Fourtouna A, Maslon MM, Naughton C, Langdon S, Murray E, Larianov A, Petrakova K, Muller P, et al: The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene 29: 4838-4847, 2010.

31. Wilson CL, Sims AH, Howell A, Miller CJ and Clarke RB: Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 13: 617-628, 2006.